معرفی
Gijs van Praagh is a researcher specializing in nuclear medicine and medical imaging, with a focus on PET-CT applications for vascular inflammatory diseases. His work primarily investigates the use of radiotracers like 18F-FDG and Na18F in diagnosing and monitoring conditions such as giant cell arteritis, large vessel vasculitis, and vascular graft infections.
His research interests center on applying radiomics and machine learning to medical imaging data to improve diagnostic accuracy in vascular inflammatory diseases. He explores quantitative analysis of PET-CT images to differentiate between active disease states, infections, and normal physiological processes, particularly in the context of large vessel vasculitis and related conditions. His work bridges clinical medicine with advanced image analysis techniques to develop more precise diagnostic tools.
Dr. van Praagh's publication record shows a strong focus on the clinical applications of PET imaging in vascular diseases. His recent work examines FDG-PET patterns in polymyalgia rheumatica, radiomic features for identifying active giant cell arteritis, and quantitative assessment of vascular calcification. The research demonstrates an evolving trend toward integrating machine learning with traditional imaging metrics to enhance diagnostic capabilities in inflammatory vascular conditions.
His scientific contributions include multiple peer-reviewed articles in journals such as Diagnostics, European Journal of Nuclear Medicine and Molecular Imaging, and EJNMMI Research. These publications reflect his expertise in applying nuclear medicine techniques to solve clinical challenges in vascular inflammation and infection diagnosis.
Dr. van Praagh collaborates extensively with researchers in nuclear medicine and rheumatology, particularly with Slart, R.H.J.A. and van der Geest, K.S.M. His work contributes to advancing diagnostic protocols for large vessel vasculitis and related inflammatory conditions, with potential implications for improving patient management and treatment monitoring.
